Unlocking the potential: advancements and future horizons in ROR1-targeted cancer therapies
- 12 August 2024
- journal article
- review article
- Published by Springer Nature in Science China Life Sciences
- Vol. 67 (12) , 2603-2616
Abstract
While receptor tyrosine kinase-like orphan receptor 1 (ROR1) is typically expressed at low levels or absent in normal tissues, its expression is notably elevated in various malignant tumors and conditions, including chronic lymphocytic leukemia (CLL), breast cancer, ovarian cancer, melanoma, and lung adenocarcinoma. This distinctive feature positions ROR1 as an attractive target for tumor-specific treatments. Currently, several targeted drugs directed at ROR1 are undergoing clinical development, including monoclonal antibodies, antibody-drug conjugates (ADCs), and chimeric antigen receptor T-cell therapy (CAR-T). Additionally, there are four small molecule inhibitors designed to bind to ROR1, presenting promising avenues for the development of PROTAC degraders targeting ROR1. This review offers updated insights into ROR1’s structural and functional characteristics, embryonic development implications, cell survival signaling pathways, and evolutionary targeting strategies, all of which have the potential to advance the treatment of malignant tumors.Keywords
This publication has 89 references indexed in Scilit:
- Exploration of macrocyclic peptide binders to the extracellular CRD domain of human receptor tyrosine kinase-like orphan receptor 1 (ROR1)Bioorganic & Medicinal Chemistry Letters, 2023
- Estrogen receptor alpha and NFATc1 bind to a bone mineral density-associated SNP to repress WNT5B in osteoblastsThe American Journal of Human Genetics, 2022
- Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules2021
- A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib‐resistant ROR1+ CLL cellseJHaem, 2021
- The emerging role of Wnt5a in the promotion of a pro-inflammatory and immunosuppressive tumor microenvironmentCancer and Metastasis Reviews, 2020
- Novel ROR1 inhibitor ARI-1 suppresses the development of non-small cell lung cancerCancer Letters, 2019
- ROR1 contributes to melanoma cell growth and migration by regulating N‐cadherin expression via the PI3K/Akt pathwayMolecular Carcinogenesis, 2015
- ROR1, an embryonic protein with an emerging role in cancer biologyProtein & Cell, 2014
- Protein tyrosine kinase regulation by ubiquitination: Critical roles of Cbl-family ubiquitin ligasesBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2013
- Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapyInternational Journal of Cancer, 2008